Jia Shijing, Taylor-Cousar Jennifer L
Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA; email:
Divisions of Pulmonary Sciences and Critical Care Medicine and Pediatric Pulmonology, National Jewish Health, Denver, Colorado, USA; email:
Annu Rev Med. 2023 Jan 27;74:413-426. doi: 10.1146/annurev-med-042921-021447. Epub 2022 Aug 16.
Cystic fibrosis (CF) is an inherited multisystemic disease that can cause progressive bronchiectasis, pancreatic endocrine and exocrine insufficiency, distal intestinal obstruction syndrome, liver dysfunction, and other disorders. Traditional therapies focused on the treatment or prevention of damage to each organ system with incremental modalities such as nebulized medications for the lungs, insulin for diabetes, and supplementation with pancreatic enzymes. However, the advent of highly effective modulator therapies that target specific cystic fibrosis transmembrane conductance regulator protein malformations resulting from individual genetic mutations has transformed the lives and prognosis for persons with CF.
囊性纤维化(CF)是一种遗传性多系统疾病,可导致进行性支气管扩张、胰腺内分泌和外分泌功能不全、远端肠梗阻综合征、肝功能障碍及其他病症。传统疗法侧重于采用渐进性方式治疗或预防对各个器官系统的损害,如使用雾化药物治疗肺部、胰岛素治疗糖尿病以及补充胰酶。然而,针对由个体基因突变导致的特定囊性纤维化跨膜传导调节蛋白畸形的高效调节剂疗法的出现,改变了囊性纤维化患者的生活和预后。